Enhancing Patient Care Through Digital Monitoring in HER2-Positive Breast Cancer Treatment
Exploring the TOP-REAL Study
The ongoing clinical research initiative known as TOP-REAL aims to improve the treatment experience for patients suffering from HER2-positive metastatic breast cancer. This innovative study is spearheaded by Solti in Spain, with collaboration from Unicancer in France and the West German Study Group (WSG) in Germany. Recently presented at the ESMO AI & Digital Oncology 2026 conference, the trial seeks to integrate digital monitoring tools that offer real-time insight into patient symptoms and physiological conditions between hospital visits.
Objective of the Study
As cancer treatments have advanced, particularly for HER2-positive breast cancer, managing treatment-related toxicities has emerged as a critical component in supporting patient care. The TOP-REAL study investigates whether proactively monitoring patients can lead to early detection of toxicities, preventing complications that could disrupt the effectiveness of first-line therapies such as trastuzumab deruxtecan (T-DXd) combined with pertuzumab. The central paradigm is to shift from a reactive care model to a proactive one that centers on the patient's experience and well-being during treatment.
Innovative Monitoring Strategies
The study involves approximately 300 patients, stretching across 60 centers across Spain, France, and Germany, collecting diverse data that reflects real-world patient demographics. By utilizing tools such as electronic patient-reported outcomes (ePROs) and advanced continuous monitoring via smartwatches, the research aims to generate alerts for clinicians in cases of adverse symptoms. Daily monitoring of oxygen saturation and exercise capacity will be particularly focused on assessing conditions like interstitial lung disease and pneumonitis associated with T-DXd.
Dr. Cristina Saura, the principal investigator, articulates the dual focus of the study: “We want patients not only to benefit from advances that allow better control of their disease, but also to experience a better quality of life during treatment.” This pioneering observational study aims to ensure that patient-centric approaches are embedded within clinical practice, ensuring that those with challenging profiles such as brain metastases are equally represented.
Bridging the Gap Between Research and Practice
The project acknowledges that emerging cancer therapies may extend patient survival but also require enhanced attention to the quality of life. The study strategy includes evaluating how quickly patients can return to subsequent cancer treatments and the overall impact of their health-related quality of life, assessed through the EORTC QLQ-C30 questionnaire.
Prof. Nadia Harbeck, another principal investigator, emphasizes the study's capabilities to better integrate effective treatments into clinical frameworks. The findings of TOP-REAL could unravel whether the observed benefits from T-DXd plus pertuzumab can translate into routine applications while ensuring robust management of potential toxicities through digital tools.
Implications for Future Treatments
TOP-REAL not only highlights the necessity of toxicity management within the rapidly evolving landscape of HER2-positive breast cancer treatment but also illustrates how digital health innovations can fundamentally reshape patient experiences in oncology. This includes a mobile application facilitating symptom reporting, continuous physiological assessments, and clinician alerts regarding patient health status—each contributing step towards proactive healthcare.
In conclusion, the TOP-REAL study revolutionizes how healthcare providers approach patient treatment in oncology by offering a more integrated, technology-driven method that prioritizes early detection of side effects and enhances overall care. This research holds promise not just for HER2-positive breast cancer patients, but also for the future of cancer treatment protocols in general, establishing a framework for patient-centered care that can be adapted universally across healthcare systems.